Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Endocrine 1

Conditions

Prostatic Neoplasms 3Metastatic Neuroendocrine Prostate Cancer 1

Interventions

Specimen Handling 258Magnetic Resonance Spectroscopy 213pembrolizumab 202Carboplatin 170Cisplatin 137Biopsy 133Cyclophosphamide 130Paclitaxel 120Nivolumab 109Gemcitabine 102Bevacizumab 102Radiotherapy 81Dexamethasone 77Pemetrexed 75atezolizumab 71Fluorouracil 71fludarabine 68Doxorubicin 67Leucovorin 66Docetaxel 65Radiation 64Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 57Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × gallium 68 PSMA-11 × 30 days × Clear all
NCT06379217 2026-06-03

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT04720157 2026-05-27

PSMAddition

Novartis

Phase 3 Active not recruiting
1,140 enrolled
Genitourinary

Prostatic Neoplasms

NCT05849298 2026-05-27

PSMACare

Novartis

Phase 2 Active not recruiting
49 enrolled
Genitourinary

Prostatic Neoplasms

NCT03582774 2026-05-26

PSMA SRT

Jonsson Comprehensive Cancer Center

Phase 3 Active not recruiting
193 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡